NCT07612878 The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
| NCT ID | NCT07612878 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sanofi |
| Condition | COPD (Chronic Obstructive Pulmonary Disease) |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2026-08-06 |
| Primary Completion | 2029-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2026-08-06 with a primary completion date of 2029-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.
Eligibility Criteria
Inclusion Criteria: * COPD patients who are newly referred to start dupilumab treatment * Age ≥ 40 years * Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit Exclusion Criteria: * Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI) * Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments * Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07612878 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying COPD (Chronic Obstructive Pulmonary Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07612878 currently recruiting?
Yes, NCT07612878 is actively recruiting participants. Contact the research team at Contact-us@sanofi.com for enrollment information.
Where is the NCT07612878 trial being conducted?
This trial is being conducted at Indianapolis, United States, Durham, United States, North Richland Hills, United States.
Who is sponsoring the NCT07612878 clinical trial?
NCT07612878 is sponsored by Sanofi. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.